Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.40 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.39 |
| ▸ | HPGDS | O60760 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18785081 | 1.00 | MEN1 (0.47) | MEN1KMT2AABL1RIN1KDM4E | |
| SCHEMBL20598279 | 1.00 | MEN1 (0.47) | MEN1KMT2AABL1RIN1KDM4E | |
| SCHEMBL18785083 | 1.00 | MEN1 (0.47) | MEN1KMT2AABL1RIN1KDM4E | |
| SCHEMBL17328224 | 0.96 | KMT2A (0.46) | MEN1KMT2AKDM4EPKMSCD5 | |
| SCHEMBL18785466 | 0.85 | MEN1 (0.49) | MEN1KMT2AABL1RIN1KDM4E | |
| SCHEMBL20598278 | 0.85 | CYP2D6 (0.47) | ALDH1A1GPR119MGLL | |
| SCHEMBL20598276 | 0.85 | CYP2D6 (0.47) | ALDH1A1GPR119MGLL | |
| SCHEMBL19107365 | 0.85 | MAPK1 (0.46) | MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL20598617 | 0.85 | CYP2D6 (0.47) | ALDH1A1GPR119MGLL | |
| SCHEMBL18785463 | 0.85 | CYP2D6 (0.47) | ALDH1A1GPR119MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-06-23 | — | — | US | disclosed |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689398-B2 | OXA-Diazaspiro compounds having activity against pain | OPRD1, SIGMAR1, OPRK1 | MEN1 4855/4885KMT2A 4584/4885ABL1 3830/4885 |
| US-20190002475-A1 | OXA-DIAZASPIRO COMPOUNDS HAVING ACTIVITY AGAINST PAIN | OPRD1, SIGMAR1, OPRK1 | MEN1 4855/4885KMT2A 4584/4885ABL1 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.